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Abstract
Tuberculosis (TB) is an escalating global health problem and improved vaccines against TB are urgently needed. HLA-E
restricted responses may be of interest for vaccine development since HLA-E displays very limited polymorphism (only 2
coding variants exist), and is not down-regulated by HIV-infection. The peptides from Mycobacterium tuberculosis (Mtb)
potentially presented by HLA-E molecules, however, are unknown. Here we describe human T-cell responses to Mtb-derived
peptides containing predicted HLA-E binding motifs and binding-affinity for HLA-E. We observed CD8
+ T-cell proliferation to
the majority of the 69 peptides tested in Mtb responsive adults as well as in BCG-vaccinated infants. CD8
+ T-cells were
cytotoxic against target-cells transfected with HLA-E only in the presence of specific peptide. These T cells were also able to
lyse M. bovis BCG infected, but not control monocytes, suggesting recognition of antigens during mycobacterial infection.
In addition, peptide induced CD8
+ T-cells also displayed regulatory activity, since they inhibited T-cell proliferation. This
regulatory activity was cell contact-dependent, and at least partly dependent on membrane-bound TGF-b. Our results
significantly increase our understanding of the human immune response to Mtb by identification of CD8
+ T-cell responses
to novel HLA-E binding peptides of Mtb, which have cytotoxic as well as immunoregulatory activity.
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Introduction
Tuberculosis (TB) remains a major health burden with one-
third of the world population infected with Mycobacterium tuberculosis
(Mtb) and 1.7 million deaths annually [1]. The currently available
vaccine, M. bovis Bacillus Calmette Guerin (BCG), induces variable
protection; although it protects well against severe childhood forms
of TB, its ability to protect against pulmonary TB regardless of age
is highly variable and at best partly [2,3] urging the search for
better vaccines [4]. The HIV pandemic has increased TB disease
incidence in recent years, and vaccines which are effective and safe
in HIV-infected individuals are urgently needed. After decades of
neglect, the search for new vaccines against TB has only recently
been reinitiated, but thus far few if any vaccines have been able to
induce protection superior to that of BCG in animal models [4].
Optimal vaccine development requires insight into the mech-
anisms of protective host immunity. The immune response elicited
upon Mtb infection is complex and incompletely understood. One
of the most studied effector molecules of anti-Mtb immunity is
IFNc, which is produced predominantly by CD4
+ T- and NK-
cells. Effector immunity mediated by CD8
+ T-cells has been less
well characterized, and work reported thus far has focused almost
exclusively on CD8
+ T-cell responses restricted by classical HLA
class Ia or CD1 a,b,c molecules [5]. The human HLA class I
family comprises both classical (class Ia) and non-classical (class Ib)
members. The former (i.e. HLA-A,-B,-C) molecules are highly
polymorphic and comprise of 506, 872 and 274 different protein
variants respectively, with large variations in potential bound
peptides. HLA class Ib genes, instead, display limited polymor-
phism: there are 3, 4 and 10 protein variants described for HLA-E,
-F and -G, respectively [6]. This minor variation between class Ib
alleles is remarkable and suggests an evolutionary distinct role for
class Ia and class Ib molecules. Non-classical HLA class I
molecules including HLA-E are able to function as antigen
presenting molecules for CD8
+ T-cells, and can present both self
and foreign (pathogen derived) antigens [7–9]. HLA-E presented
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molecules and sequences from TCR-Vb chains, the latter of which
are recognized by CD8
+ T-cells with cytotoxic (CTL) activity [10].
There is only one single amino acid difference between the
different HLA-E proteins; this coding variation is located at
position 107 (arginine to glycine) on the loop between b-strands in
the a2 domain of the heavy chain, outside the peptide binding
groove [11]. The lack of allelic variation in the peptide binding
groove limits the number of possible peptides that can bind to
HLA-E, and it is highly likely that similar peptides can be
presented by both HLA-E variants [11]. The frequency of both
variants, called HLA-E
R (E*0101) and HLA-E
G (E*0103) is equal
amongst different populations suggesting balanced selection in
divers populations [12]. Whether HLA-E
R and HLA-E
G can
display functional differences has not been studied in detail
[11,12], but it has been demonstrated that HLA-E
G homozygous
cells express higher levels of HLA-E and had higher peptide
binding affinity, although this was tested in rather artificial models
only [11].
Recognition of peptides presented by HLA-E may result in
CD8
+ effector T-cell activation [7–9]. For example, HLA-E can
present antigens derived from pathogens including Mtb [13],
cytomegalovirus [7] and Salmonella typhi [9]. The nature of the Mtb
antigen(s) recognized by the only two reported human HLA-E
restricted CD8
+ T-cell clones, which produced IFNc after co-
incubation with Mtb-infected dendritic cells, remains unknown
[13].
In addition to its limited genetic polymorphism, HLA-E offers
another potential advantage in relation to vaccination in the
context of HIV, a highly prevalent co-infection in TB. In Southern
Africa alone approximately 70% of TB-patients are also HIV-
infected [14]. HIV infection down-regulates expression of HLA-A
and -B molecules through its Nef proteins, thus decreasing antigen
presentation capacities [15]. In contrast, HLA-E is resistant to
HIV-nef-mediated down-regulation due to a single amino acid
substitution in the HLA-E cytoplasmic tail [16]. Persistent
expression of HLA-E during HIV infection renders the HIV
infected cells resistant to NK-mediated lysis [16]. Thus, while HIV
might affect antigen presenting cells of the myeloid lineage like
monocytes and macrophages [17] and inhibit antigen presentation
by class Ia molecules, HLA-E dependent antigen presentation is
likely to be less affected by HIV co-infection. Thus, targeting Mtb
specific HLA-E restricted immunity by vaccination may be a novel
and advantageous approach for several reasons. Furthermore, if
BCG vaccination would already be able to prime HLA-E
restricted T-cell responses, HLA-E peptide based vaccines might
be able to boost BCG induced responses.
To date, most studies on HLA-E have focused on NK cells,
which can recognize and kill target cells via cognate HLA-E/
CD94-NKG2A interactions. As described above, a limited
number of studies has shown that direct recognition of patho-
gen-derived antigen presented by HLA-E can occur via the T-cell
receptor (TCR) [18,19]. Recognition of specific peptides presented
by HLA-E was found to result in CTL activity directed towards
the peptide presenting cell [18,19]. The molecular interactions
between the TCR and HLA-E have not been studied extensively,
and particularly, HLA-E peptide binding motifs have been
determined only in relation to interactions of HLA-E with
CD94/NKG2 receptors [20]. The peptide anchor residues critical
for peptide binding to HLA-E might be conserved in both cases,
but the residues at position 5 and 8, which are critically involved in
the interaction with NKG2 [20] may be more variable for
interactions with the TCR. However, in a study analyzing
recognition of CMV UL40 derived peptide by a single TCR,
peptide position 8 seemed critical for discrimination between self
and non-self [21]. Crystallography revealed an interaction that
mimicked the typical TCR-MHC class Ia complexes [21]. T-cells
restricted to the mouse equivalent of HLA-E, Qa-1, are positively
selected in the thymus, demonstrating specific recognition of Qa-1-
peptide complexes in early T-cell development [22]. Thymic
selection of Qa-1 restricted T-cells furthermore suggests positive
selection of such T-cells in vivo as relevant immune players.
Interestingly, detailed analysis of Qa-1 restricted CD8 T-cells in
mice revealed suppressive capacities of these cells [23]. Suppres-
sion was specifically directed towards T-cells with intermediate
avidity independent of the antigen, thus downregulating both self
and non-self specific T-cells [24].
To start unraveling antigen specific human HLA-E restricted T-
cell responses in the context of TB, we have used bioinformatics,
HLA-E peptide-binding assays and functional characterization of
the responding T-cells, in order to identify and characterize
potential CD8
+ T-cells that recognize Mtb peptides in the context
of HLA-E.
Results
Epitope prediction
In terms of its bound peptidome, HLA-E remains a largely
uncharacterized MHC class I molecule. This prompted us to use
bioinformatics and in vitro peptide/HLA-E binding affinity assays
to identify possible T-cell epitopes presented by this molecule.
Given the limitation of available resources, a highly guided
approach was used which combined the use of legacy peptides,
including known HLA-E binders (i.e. MHC class I leader
sequences), the use of partial binding data [20] and iterated use
of discriminant analysis (DA) and diversity analysis to suggest
peptides for testing (Table 1) [25].
DA often outperforms other approaches analyzing MHC-
peptide binding because the method results in classification by
class, from multiple data sources, regardless of the affinity measure
used to identify binders [25]. Likewise, a peptide eluted from cell-
surface MHC must obviously be able to bind, with reasonable
Author Summary
Mycobacterium tuberculosis (Mtb) has infected about one-
third of the world population, resulting in fatal pulmonary
tuberculosis (TB) in 1.5 million people annually. Vaccina-
tion against Mtb has decreased disease incidence in young
children but does not prevent pulmonary TB in adults. The
immune response against Mtb comprises multiple players,
one of which is the CD8
+ T-cell. CD8
+ T-cells recognize
infected cells because Mtb derived peptides are presented
on HLA class I molecules. Here, we studied the non-
classical HLA molecule HLA-E as presenter of Mtb antigens.
The Mtb genome contained multiple sequences that can
be presented by human HLA-E. These peptides were
recognized by CD8
+ T-cells from healthy individuals that
were sensitized to Mtb, resulting in CD8
+ T-cell prolifera-
tion. These T-cells lysed mycobacterium infected cells in a
HLA-E restricted manner. Additionally, these T-cells also
inhibited proliferation of other T-cells in their vicinity, a
property of regulatory T-cells. The dual functionality of
these T-cells makes them interesting players during
infection, probably balancing their function depending
on the environment. These findings contribute to our
understanding of the immune response towards Mtb and
will be helpful in designing new and improved vaccines
against TB.
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# Sequence
Derived
from
Accession
number*
HLA-E
motif score
a
Discrimination
score
b
Diversity
ranking
c
Binding
(in uM)
1 SMADRAENL Rv1286 Q10600 268 .50
2 SMAGRAGQL Rv3282 P96887 268 .50
3 IMANRAQVL Rv3532 Q6MWW4 268 0,4
4 KMNAKAATL Rv2911 Q7D6F2 263 15
5 QMKFYAVAL Rv2119 O33254 260 1,5
6 PMKRTALAL Rv0959 P0A5D7 259 18
7 GMNVTAPAL Rv1617 O06134 257 8
8 VMADRTRHL Rv0418 P96264 255 5
9 WMCDRAVDL Rv2954c Q50461 254 .50
10 LMVVRALFL Rv3101c P96293 254 nt
11 EMVLRADQL Rv0191 O07435 253 .50
12 DMLGRAGGL Rv3015c O53262 253 .50
13 MMKYLAFGL Rv0206c O53657 246 0,4
14 RMAATAQVL Rv2932 Q10978 237 2
15 FLAADALVL Rv1047 P96354 185 .50
16 VEAFRTRPL Rv1047 P96354 189 .50
17 LMGAEADAL Rv1047 P96354 210 .50
18 GLDSRAYRL Rv0146 O86321 212 .50
19 GLDARAYRL Rv0145 P96356 212 .50
20 PMAPLAPLL Rv3871 O69736 226 3
21 EMKTDAATL Rv3874 P0A566 246 .50
22 PMQQLTQPL Rv3873 Q79F92 205 .50
23 PMADIAAAL Rv1253 Q11039 225 .50
24 ALPPRAFEL Rv3428c Q50700 212 0,27
25 AMVNTTTRL Rv2074 Q10682 209 20
26 LMGALAVVL Rv2075c Q10683 211 21
27 VSNLRTGKL Rv1967 O53968 208 .50
28 TSADRAVVL Rv1973 O53974 203 39
29 LMHYRGELL Rv1965 O53966 201 20
30 NMMARGMDL Rv0221 P96403 201 .50
31 LPAERAHEL Rv0222 P96404 202 .50
32 VMMSEIAGL Rv1813c P64889 348 13
33 TMITFRLRL Rv1733c P71991 373 2,4
34 VMTTVLATL Rv1734c P71992 348 1,8
35 GMGMVGTAL Rv1737c P71995 348 .50
36 AMAGSIDLL Rv2006 Q10850 367 34
37 EMLTSRGLL Rv1997 P63687 352 .50
38 QMRACARRL Rv2004c P0A5F9 210 1,5
39 AMEYFRQVL Rv2006 Q10850 348 28
40 SMFAAVQAL Rv2030c O53475 375 5
41 HMAQTLGSL Rv2030c O53475 185 .50
42 SMFAAVQAL Rv2030c O53475 357 2,5
43 EMGRAPLDL Rv2627c O06185 373 .50
44 RLPAKAPLL Rv1484 P0A5Y6 1,347 0,03
45 VMAPLGPIL Rv1405c P64841 NA 0,8
46 QLAPGLQLI Rv1563c Q10768 1,248 .50
47 RLAPGGTTI Rv0068 O53613 1,238 .50
48 RLANLLPLI Rv3189 O53335 1,231 32
49 ILPSDAPVL Rv3823c O07800 NA 0,2
HLA-E Restricted Mtb Specific CD8
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a T-cell epitope must, again, have bound to MHC prior to T cell
recognition. Thus, all of these conceptually distinct ways of
classifying peptides will yield equivalent definitions of binders
versus non-binders. This allows a DA-based approach to
rationalize a wide array of data. Other methods may weigh
contributions from high-affinity peptides more than lower-affinity
peptides, whereas DA will always weigh contributions equally
according to class and will therefore generate sets of peptides with
a greater probability of being active [25]. This prediction was
complemented by diversity analysis to identify a set of peptide
sequences which combined high potential binders with high
diversity in terms of position-dependent physical properties as
encoded using composite scores [26,27]. Combination of all
bioinformatics methods resulted in selection of 69 potential HLA-
E binding peptides from the total Mtb H37Rv genome for detailed
binding and immunological assays (Table 1).
Binding assays
Peptides were synthesized and were tested for binding to
recombinant human HLA-E*0103 in a competition assay, using a
fluorescently labeled natural ligand [28] as the standard HLA-E
binding peptide, and the predicted HLA-E peptides (n=69) as
competitors. Binding affinity (IC50,50 mM) was observed for 36 out
of 68 peptides tested (53%), 18 peptides had a relatively high binding
affinity for HLA-E (IC50,5 mM) (Table 1). As found for other HLA
moleculesaswell[29],actualaffinitiesdeterminedinthisbiochemical
cell free binding assay did not fully correlate with epitope prediction
scores derived from bioinformatics (Table 1). Therefore we decided
to test all 69 peptides for recognition by T-cells.
T-cell proliferation is induced by predicted HLA-E binding
Mtb peptides in the context of HLA-E
All predicted HLA-E binding peptides were tested for their
capacity to induce CD8
+ T-cell proliferation as measured by
CFSE dilution. Proliferating CD3
+CD8
+CD56
2 T-cells were
gated, thus excluding NK and CD4
+ T-cells. We first assessed
proliferation in PBMCs from healthy adult volunteers from the
Netherlands who produced IFNc (n=10) or lacked IFNc (n=10)
in response to Mtb-derived PPD. In all cases, unstimulated PBMC
failed to proliferate whereas positive control mitogen (PHA)
stimulated cells proliferated strongly (Figure 1). Proliferative
responses were defined as .10% proliferating CD3
+CD8
+CD56
2
T-cells based on CFSE dilution (see M&M section for details).
Each of the 10 PPD-respondingindividuals tested recognized one
or more of the 69 peptides (Figure 2A). There was significant inter-
individual heterogeneity in the peptide repertoire recognized by the
donors, and peptidesthat inducedproliferationinonedonordidnot
# Sequence
Derived
from
Accession
number*
HLA-E
motif score
a
Discrimination
score
b
Diversity
ranking
c
Binding
(in uM)
50 VLLPGLPYL Rv3847 P96230 1,208 8
51 REPRRGPRL Rv0142 P96819 1,169 1 .50
52 RLRPELAGL Rv3772 P72039 0,755 3 46
53 RELPGRVLL Rv3094c O05773 0,759 4 .50
54 FLLPRGLAI Rv0056 P66315 0,867 5 .50
55 VMATRRNVL Rv1518 Q50590 0,924 6 16
56 RLGRLLNRI Rv3737 O69704 0,825 7 .50
57 IEPRGAQAL Rv0171 O07415 0,985 8 .50
58 DLPSRLGKI Rv3087 O53304 0,802 9 .50
59 RPANLAFFL Rv1188 O50444 NA 1,3
60 FMTRLGPLL Rv0035 Q7DAJ8 0,829 11 37
61 RLASCRDAL Rv2761c O33303 0,775 12 .50
62 RMPPLGHEL Rv2997 O53244 1,19 13 4
63 VMAPDAVRI Rv0324 O08446 1,014 14 31
64 RSCPRLTIL Rv0894 P64749 0,895 15 .50
65 RLARRARNI Rv1513 P71792 0,773 16 .50
66 RLGLCALAL Rv3370c O50399 NA 14
67 VLPACLGIL Rv0206c O53657 0,878 18 12
68 VLRPGGHFL Rv1523 Q50584 0,767 19 1,8
69 WLPPLLTNL Rv0249c O53671 0,963 20 39
Peptides containing HLA-E binding motifs were predicted in silico using motif scores, discriminant analysis and diversity analysis. Peptide sequences are indicated as
well as the proteins their originating proteins (Mtb Rv numbers and their Swissprot accession numbers). Binding was tested by HPLC size exclusion chromatography
using recombinant human HLA-E and competition of a fluorescently labeled peptide [33]. Binding was calculated as the concentration (mM) of peptide required to
reduce fluorescence intensity of the standard peptide with 50% (IC50).
*UniProtKB/ Swissprot accession number.
aIdentified through ‘‘motif’’ score, i.e. weighting positions differently.
bTop five from a discriminant analysis: binder vs non-binder.
cTop Twenty-odd from diversity analysis of peptide sequences with high discriminant scores.
NA, not available.
doi:10.1371/journal.ppat.1000782.t001
Table 1. Cont.
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Most donors recognized multiple predicted HLA-E binding
epitopes (range 1–27, median 5). Conversely, 55/69 peptides
(79%) were recognized by at least one PPD responder. Nine
peptides were recognized by 3 independent adult donors and 2
peptides (#14 and 62) were even recognized by 4 PPD responding
adult donors. Peptide sequence analysis did not reveal a structural
motif associated with frequent recognition (data not shown).
Compared to PPD responders, PPD nonresponsive donors showed
much lower, though not undetectable frequencies of peptide
responses (Figure 2A, 2C; p=0.028). Five out of 10 non-PPD-
responders did not recognize any of the peptides tested, whereas the
other 5 donors recognized up to 6 peptides (overall range 0–6,
median 1). One peptide (#13) which was recognized by 3 non-
responder donors, revealed a broad presence in many mycobacte-
rial strains, including M. marinum, M. ulcerans, M. smegmatis and M.
leprae but likely also others, suggesting that T-cell proliferation may
have resulted from cross-reactivity with ubiquitously present non-
tuberculous mycobacterial species. Finally, there was no clear
correlation between the number of peptides recognized and the
levels of IFNc produced following PPD stimulation in a 6-day
lymphocyte stimulation test (data not shown).
Since some of the PPD non-responder donors responded to
some of the test peptides, we decided to test cells derived from
umbilical cord bloods (UCB) considering these to be immunolog-
ically most naı ¨ve, even though it has been demonstrated that also
fetal exposure to mycobacteria can occur in utero [30]. UCBs
recognized very few of the Mtb peptides with putative HLA-E
binding Mtb peptides; three UCBs recognized none of the 69
peptides, one UCB recognized a single peptide and the remaining
UCB recognized 2 individual peptides (Figure 2A & 2C). Taken
together, these results suggest that the majority of responses
against putative HLA-E binding Mtb peptides in adults most likely
are the result of mycobacterial exposure or infection.
We next studied responses to a selection of the predicted HLA-E
binding Mtb epitopes in a second, independent cohort of 10-week
old South African infants that were routinely vaccinated with BCG
at birth (n=12). Proliferative responses in PBMC against predicted
HLA-E binding peptides were observed in 6 out of 12 infants tested
(Figure 2B). All 6 infants recognized 2 or more peptides. Six infants
did not recognize any of the 10 peptides tested, despite detectable
PPD responses. Infant #8 recognized all peptides tested but to a
variable extent (range 23–53% of CD8
+ T-cells). In line with the
observations above the high affinity HLA-E binding peptides #62
and #48 were recognized with high efficiency. By contrast, peptide
61 was recognized by 2 BCG vaccinees, but not by any of the PPD
responsive Dutch donors, suggesting possible differences in the
induction of peptide specific responses between BCG vaccination
and natural (NTM) exposure, or different ethnic groups, or both. In
this setting, it was not possible to include control infants from the
same geographic region since all infants routinely receive BCG
within 24 hours after birth.
Taken together, the results indicate that CD8
+ T-cells
recognizing Mtb peptides containing a predicted HLA-E binding
motif are detected preferentially and with appreciable frequencies
in individuals responsive to PPD as well as in infants vaccinated
with BCG. Of interest also is that the observed variation in peptide
recognition patterns points to a relatively large array of HLA-E
presented epitopes.
CD8
+ T-cell proliferation against the predicted HLA-E binding
Mtb peptides in polyclonal PBMC cultures might also (partially)
have resulted from presentation by classical HLA class I molecules,
due to possibly similar peptide binding motifs. To demonstrate
that peptides presented by HLA-E can result in T-cell prolifer-
ation, K562 cells lacking endogenous HLA molecules but
expressing only HLA-E were loaded with peptide and co-cultured
with purified CD8
+ T-cells. In this system no soluble peptide was
present, thus also excluding T-T cell presentation [31]. CD8
+ T-
cell proliferation was observed in response to the selected peptides
only when the target cells expressed HLA-E and had been peptide
loaded. No such responses could be detected in the absence of
HLA-E (Figure 2D). These data demonstrate that Mtb peptides
presented by HLA-E can induce CD8
+ T-cell proliferation.
T-cell lines reactive with predicted HLA-E binding
peptides have cytotoxic activity
To investigate the functional and phenotypical characteristics of
the putative HLA-E binding peptide responding T-cells in more
detail, we examined responses in 3 donors (2, 4, 6) against 4
peptides (54, 55, 62, 68) using peptide specific T-cell lines. Peptides
and donors were selected based on the following criteria: 1. donors
Figure 1. Predicted HLA-E binding Mtb peptides induce T-cell
proliferation. CFSE-labeled PBMCs of 20 donors were stimulated with
10 mg/ml of peptide in the presence of IL-7, on day 7 low dose IL-2 was
added and at day 10 proliferation was assessed by flowcytometry. Plots
are gated on CD3
+CD8
+CD56
2 cells in the lymphocyte gate, the
percentage of proliferation indicated is within CD3
+CD8
+CD56
2 cells.
Peptide and donor numbers correspond to the numbers in Table 1.
doi:10.1371/journal.ppat.1000782.g001
HLA-E Restricted Mtb Specific CD8
+ Tregs
PLoS Pathogens | www.plospathogens.org 5 February 2010 | Volume 6 | Issue 2 | e1000782Figure 2. PPD responders and BCG vaccinated infants recognize predicted HLA-E binding peptides derived from Mtb. (A) Summary
of all proliferation data from 10 PPD responders and 10 PPD non-responding donors. Proliferation was calculated using the following formula:
Geometric mean of undivided population minus geometric mean of all cells. Subsequently the percentage was calculated by: (delta geo mean of
sample- delta geo mean of negative control)/ delta geo mean of maximal proliferation (PHA). Samples with 10% specific proliferation or more were
considered positive (black boxes). Blue highlights identify the peptides that were selected for detailed analysis. Umbilical cord blood (UCB) (n=5) cell
proliferation was assessed by the percentage of proliferating CD3
+CD8
+CD56
2 cells and proliferation .10% was considered positive. (B) PBMCs from
BCG vaccinated infants (n=12) were tested in the same way as the cells from PPD responders for 10 selected peptides. Proliferation of 5–10% is
indicated in grey and proliferation .10% in black. (C) Comparison of PPD responders, non-responders & cord blood samples for peptide recognition,
i.e. the number of peptides recognized per donor (n=10 for adults, n=5 for cord blood). Analyzed using Students T-test with a p,0.05 considered
significant. (D) CD8
+ T cells were purified from PBMCs by magnetic bead separation of donors 2,4 and 6 and proliferation (CFSE) in response to
peptide pre-pulsed K562 cells with (right plots) or without (left plots) HLA-E was assessed. Plots are gated on CD8
+CD56
2 cells and CFSE dilution is
plotted.
doi:10.1371/journal.ppat.1000782.g002
HLA-E Restricted Mtb Specific CD8
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T cell proliferation in that specific donor; 3. peptides were not
recognized by PPD non-responders and 4. sufficient PBMCs
available for detailed analysis. The 3 donors were fully typed for all
HLA class I alleles, and prediction algorithms were run using HLA
types of the donors and the selected peptides using the syfpeithi
database (www.syfpeithi.de). The probability of peptide binding to
HLA class Ia molecules was low for most donor-peptide
combinations, further supporting that the observed CD8
+ T-cell
reactivity was mostly the result of HLA-E/TCR interactions. This
is also supported by the above finding that K562 cells presenting
Mtb peptides via HLA-E but not HLA class Ia can induce CD8
+
T-cell proliferation.
T-cell lines were generated by peptide stimulation and mostly
displayed a CD3
+CD8
+CD56
2CD16
2TCRab
+ phenotype, with
a minority of CD56
+ cells, as well as a subset expressing CD94
(Figure 3A). NKG2 family receptors were not abundantly
expressed; of two lines tested neither expressed the activating
NKG2C receptor. In contrast one line expressed the inhibitory
NKG2A receptor on about 10% of its cells. Both lines however
expressed NKG2D (Figure 3A, B). The majority of cells expressed
‘‘cell mediated cytotoxicity’’ markers: granzyme B, granulysin and
low levels of perforin (Figure 3). Interestingly, several T-cell lines
also displayed a phenotype partially compatible with regulatory T-
cells, although not all classical markers were expressed: T-cells
expressed high levels of CD25 and LAG-3 in the absence of
CD127, but lacked FoxP3, GITR or CTLA4 (Figure 3A). All 4 T-
cell lines had a remarkably similar phenotype, with the exception
of IFNc production, which was produced by only 2 out of 4 lines
upon activation (Figure 3B).
Next, to determine the cytotoxic potential of the peptide
generated T-cells in the exclusive context of HLA-E, we used
K562 cells expressing HLA-E in the absence of any other HLA class
I molecules. Untransfected K562 cells and HLA-E/HLA-B7 signal
sequence transfected K562 cells were used as controls. Cells were
loaded with peptide, labeled with
51Chromium and co-cultured with
peptide induced effector T-cells. HLA-E expression on target cells
was verified before each experiment. Co-expression of the natural
HLA-E ligand, HLA-B7 signal sequence, induced HLA-E expres-
sion on the cell surface, detectable with both the HLA-E specific
monoclonal antibody 3D12 as well as the pan HLA class I antibody
W6/32, that also recognizes HLA-E (Figure 4A). Similarly, peptide
loading of HLA-E transduced cells also induced equal surface
expression detectable by both antibodies (Figure 4A).
The peptide 55 specific T-cell line specifically lysed HLA-E
expressing target cells loaded with peptide 55 but not peptide 68.
Control cells expressing HLA-E containing the HLA-B7 signal
sequence were not recognized by these T-cells, thus confirming
peptide specific recognition in the context of HLA-E (Figure 4B,
left plot). The results were further supported by the observation
that a T-cell line generated against peptide 62 specifically lysed
K562 cells loaded with peptide 62 only in the presence of HLA-E
(Figure 4B, right plot). Cytotoxicity was observed in all 4 T-cell
lines and was consistently specific for the specific cognate Mtb
peptide used to generate the T-cell line, and strictly required HLA-
E expression. Taken together, these results demonstrate that T-cell
lines generated against predicted HLA-E binding peptides are
capable of recognizing and subsequently lysing target cells only
when cognate peptide is presented by HLA-E, but not when
irrelevant HLA-E binding peptides are presented.
Recognition of peptide loaded targets, however, does not
demonstrate direct recognition of antigens on mycobacterium
infected cells. To investigate this, HLA-A,B,C fully mismatched
monocytes were infected with live M. bovis BCG, labeled with
51Cr
and co-cultured with peptide specific T-cell lines. All 4 T-cell lines
testedwere able to lyse BCGinfected, butnotuninfectedmonocytes
(Figure 4C), although the level of killing varied between different T
cell lines. A controlCD8
+ cytotoxic T cell clone specific for the male
HY antigen did not lyse BCG infected monocytes (Figure 4C),
whereas it potently recognized the male HY antigen presented by
Figure 3. Surface-, functional- and Treg marker- phenotypes of predicted HLA-E binding peptide specific T-cell lines. (A) CD8
+ T-cell
lines were generated by peptide stimulation, and activated with aCD3/28 for 24 hours before staining. Brefeldin A was added for the last 16 hours
only (3 mg/ml). Cells are gated on a lymphocyte gate combined with CD3 and CD8 gates. (B) Summary of phenotyping data from 3 donors and 4
peptides selected for further detailed analysis.
doi:10.1371/journal.ppat.1000782.g003
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that T-cells generated against single HLA-E binding Mtb peptides
can recognize live mycobacterium infected monocytes.
Peptide specific T-cell lines also have regulatory
capacities
As mentioned above, the HLA-E/peptide specific T-cells also
expressed several markers that have been associated with human
CD8
+ Tregs, notably CD25 and LAG-3 in the absence of CD127
[32], although they did not express FoxP3, GITR and CTLA4
(Figure 3). Interestingly, mouse T-cells restricted to the murine
equivalent of HLA-E, Qa-1, display potent Treg activity [23]. For
these reasons we decided to test whether T-cell lines specific for
predicted HLA-E binding Mtb peptides also had immunosup-
pressive activity. T-cells were co-cultured with a well-characterized
Th1 responder clone, Rp15 1-1 [32,33], which recognizes Mtb
hsp65 p3–13 peptide when presented by HLA-DR3. Using this
previously reported, well-standardized read-out system [32], all 4
lines tested were found to suppress proliferation of the responder
clone in a dose dependent fashion (Figure 5A).
To exclude the possibility that the reduced proliferation of the
responder clone was the consequence of responder cell lysis, we
performed a series of additional experiments. First, HLA-E
expression was analyzed on the responder T-cell clone at various
time points after peptide-APC induced activation. We did not
observe any HLA-E expression on the responder T-cells (data not
shown), thus excluding the possibility that HLA-E peptide
recognition resulted in direct responder cell killing. However,
since alternative mechanisms might be responsible, we labeled the
Rp15-1-1 responder clone and an equal number of cells of an
irrelevant T-cell clone (added to control for input cell numbers)
pulsed with low and high doses CFSE, respectively, and added
both cells into the co-culture suppression assay. After 16 hours, a
time point prior to division of responder cells, but sufficient for
cytolysis to occur (typically detectable after 4–5 hours) fluorescent
intensities of responder and irrelevant control T-cell clones were
not altered by the addition of HLA-E/peptide induced Tregs,
irrespective of the presence of the cognate peptide of the responder
clone. Nevertheless, the addition of Tregs exerted strong
suppression of [
3H] TdR incorporation after 72 hrs. These control
experiments indicate that HLA-E/peptide induced Tregs inhibited
proliferation of, but did not lyse, responder T-cells (Figure 5B).
As shown above, the HLA-E binding Mtb peptide specific T-cell
lines had both cytotoxic and regulatory activity. Dual functionality
has been observed in polyclonal lines [32], but it remains unclear
whether these functions are exerted by the same or different T-cell
subpopulations. To investigate single vs dual functionality, single
cell derived T-cell lines or ‘clones’ were derived from limiting
dilution of a polyclonal T cell line. Three out of the 5 T-cell clones
obtained after expansion had potent regulatory activity
(Figure 5C), whereas the other 2 had no such activity. These
findings imply that only a subset of HLA-E/peptide induced T
cells has regulatory properties. The results also exclude that the
experimental protocols used to generate T-cell lines skewed
towards expansion of cells with regulatory activity.
Next, 3 of the 5 T-cell clones were tested for cytotoxic activity
towards peptide loaded HLA-E
+ target cells. One clone (4G10)
which lacked regulatory activity displayed potent cytotoxic
activity, whereas 2 other clones (3E11, 3C1) which had potent
Figure 4. Predicted HLA-E binding Mtb peptide specific T-cell
lines are cytotoxic. (A) HLA-E expression on K562 cell lines after
peptide loading. Upper graph, untransfected K562 cells do not stain
with anti-HLA-E (3D12) antibodies, whereas HLA-E transfected K562
cells expressing the natural HLA-E ligand (HLA-B7) or cells loaded with a
Mtb derived HLA-E binding peptide (#55, see Table 1) express similar
levels of HLA-E. Middle graph, similar staining is observed when an
antibody against HLA class I (W6/32) is used, with equal expression
levels of HLA-E in the presence of a natural ligand or an Mtb derived
peptide. Bottom graph, the isotype control staining for 3D12 and W6/
32 was negative on all cell lines tested. HLA-E expression was always
confirmed before functional experiments. (B) Peptide specific T-cell
lines were generated by stimulation with peptide in the presence of IL-7
and further expansion using IL-2. K562 cells expressing HLA-E were
loaded with specific and control peptides, labeled with 1 mCi
51Cr and
co-cultured with T-cell lines for 5 hours in different ratios before
51Cr
release was measured. Data are expressed as % specific lysis. Left graph:
T-cell line derived from donor 4 directed against peptide 55 (using the
high affinity HLA-E binding peptide 68 or the natural B7 ligand as
irrelevant control), right graph: T-cell line derived from donor 2 directed
against peptide 62 (using peptide 68 on transfected K562, or peptide 62
on untransfected K562 as irrelevant controls). Representative of 4 lines
derived from 3 donors. (C) Fully HLA-A,B,C mismatched adherent
monocytes were infected with live BCG (MOI 5, overnight) before
labeling with 1 mCi
51Cr. Cells were co-cultured with T-cell lines for
5 hours in 6-replicate cultures. Grey bars represent BCG infected
monocytes whereas white bars represent uninfected monocytes. All
HLA-E peptide restricted T-cell lines recognized BCG infected target
cells. In contrast a CD8
+ T-cell clone restricted to the male HY antigen
presented in HLA-A2 did not lyse infected monocytes, whereas the
natural ligand (B-cells expressing HY in the context of HLA-A2) was
specifically lysed, resulting in up to 100% target cell lysis. Data are
depicted as mean+standard error of the mean and represent multiple
experiments.
doi:10.1371/journal.ppat.1000782.g004
HLA-E Restricted Mtb Specific CD8
+ Tregs
PLoS Pathogens | www.plospathogens.org 8 February 2010 | Volume 6 | Issue 2 | e1000782regulatory activity had only moderate cytolytic activity (Figure 5D).
This demonstrates that cytotoxic and regulatory activity can be,
but are not necessarily mediated by the same HLA-E/peptide
induced cells (Figure 5C and 5D).
Membrane-bound TGFb is involved in suppression of
proliferation
Since suppression was not mediated by cellular cytotoxicity,
alternative possibilities were explored. First, supernatants were
generated by stimulating all 4 T-cell lines with cognate and control
peptides in the presence and absence of HLA-E expressing APCs,
and by stimulation with aCD3/28 (to allow maximal cytokine
production). Supernatants were collected at various time points,
and then transferred to stimulated responder T-cells. None of the
added supernatants was able to inhibit the responder T-cell clone,
whereas the physical presence of the regulatory T-cells was able to
do so (data not shown), indicating that cell-cell contact is required
for suppression. Several molecules have been described that can
Figure 5. HLA-E binding peptide specific T-cell lines have immuno-regulatory activity. (A) Peptide specific T-cell lines were generated by
stimulation with peptide in the presence of rIL-7 and further expanded with rIL-2. To investigate their potential capacity to inhibit CD4
+ T-cell activity,
they were co-cultured with a well characterized CD4 Th1 clone (Rp15 1-1 (1610e4 cells per well)) proliferating to its cognate peptide (0.5 mg/ml)
presented by HLA-DR3
+ cells. Dose-dependent addition of peptide stimulated cells (ranging from 0.6–5610e4 added T-cells) reduced proliferation of
the Th1 clone as measured by [
3H] TdR incorporation at day 3. T-cell lines generated from 3 donors directed against 3 different peptides are shown
(donor 2 against peptide 62, donor 4 against peptide 55 and donor 6 against peptide 68), the T cell line from donor 2 against peptide 54 had a similar
suppressive capacity (not shown) CPM=counts per minute. (B) To exclude that suppression was merely the consequence of lysis of the responder T-
cells, we analysed cell survival in a CFSE labeling experiment. The responder T-cell clone Rp15 1-1 was labeled with a low dose of CFSE (0.005 mM),
whereas a second, isogenic T-cell clone with a different peptide specificity and HLA-DR2 restriction (R2F10), was labeled with a high concentration of
CFSE (5 mM). Both responder and irrelevant T-cell clones were HLA-E negative. They were then co-cultured with the HLA-E binding Mtb peptide
specific T-cell lines (‘‘Treg’’) in the presence of the peptide (0.5 mg/ml) recognized by the responder clone Rp15 1-1 and HLA-DR3
+ APCs. After
16 hours CFSE intensity was measured by flowcytometry. In the absence of added Tregs, similar numbers of responder and irrelevant T-cell clones
were retrieved (ratio of 1). The addition of ‘‘Tregs’’ to peptide activated or control cultures also resulted in similar numbers of both responder and
irrelevant T-cells, thus indicating that the responder clone is not lysed by the Tregs. Simultaneously a 3 day co-culture was performed and analyzed
by [
3H] TdR uptake. This experimental set-up revealed inhibition of proliferation of the responder clone. Addition of different numbers of Tregs did
inhibit proliferation in a suppression assay but not the ratio of responder over irrelevant T-cell numbers in a CFSE intensity assay. (C) Clonal
populations were obtained by limiting dilution of the T-cell line of donor 2 against peptide 62, all derived from 0.1 cells/well cultures. Clones were co-
cultured in different ratios to Rp15 1-1 as described in (a) and 3H TdR incorporation measured. Three out of the 5 tested clones inhibited proliferation
of the indicator clone in a dose dependent manner. (D) K562 target cells selectively expressing HLA-E were loaded with peptide 62 (10 mg/ml) before
51Cr labeling, followed by 5 hour co-incubation with T-cell clones and determination of
51Cr release. Clone 4G10 strongly lysed peptide loaded target
cells, whereas 3E11 and 3C1 had moderate lysing capacity.
doi:10.1371/journal.ppat.1000782.g005
HLA-E Restricted Mtb Specific CD8
+ Tregs
PLoS Pathogens | www.plospathogens.org 9 February 2010 | Volume 6 | Issue 2 | e1000782mediate cell-cell contact dependent suppression, including CTLA4
[34], GITR [35] and, more recently, membrane bound TGFb1
[36,37]. Since our regulatory T-cell-lines did not express
significant levels of CTLA4 or GITR (Figure 3A), these molecules
were unlikely to be involved, such that we decided to examine
whether membrane bound TGFb (mTGFb) might be involved.
The function of active TGFb can be inhibited by addition of
latency associated peptide (LAP), which reverts active TGFb to a
latent, inactive form [38]. Addition of recombinant LAP to co-
culture assays indeed resulted in reversal of suppression, strongly
implicating a functional involvement of TGFb in inhibition of T-
cell proliferation (Figure 6A). Addition of LAP to the indicator
clone only resulted in an increased proliferation of maximally 20%
(data not shown), similar to previous studies [36]. However the
increased proliferation observed upon addition of LAP to co-
cultures of Tregs and indicator clones resulted in an increase of
proliferation over 40% supporting a specific reversal of suppres-
sion.
Since suppression was contact dependent and acidified
supernatants did not contain any TGFb1 as measured by ELISA
(data not shown), we assumed that TGFb was membrane bound.
Cell surface staining using a TGFb1 specific monoclonal antibody
indeed revealed the presence of mTGFb at the surface of activated
T-cell lines (Figure 6B).
Taken together, these data demonstrate that mTGFb is
expressed on HLA-E restricted, Mtb peptide reactive T-cell lines,
which have regulatory activity, and that its functional inhibition
abrogates, in part, the suppression by these T-cells. Thus, Mtb
derived peptides presented by human HLA-E are recognized by
CD8
+ T-cell populations that can exert both cytotoxic and
immunoregulatory functions, the latter involving membrane
bound TGFb.
Discussion
We describe to the best of our knowledge for the first time,
Mycobacterium tuberculosis-derived peptides that can be presented by
HLA-E molecules and are recognized by human CD8
+ T-cells.
These observations significantly extend our knowledge of the
repertoire of epitopes and human antigen presentation pathways
in mycobacterium specific host immunity, complementing current
knowledge on the well established classical HLA class Ia, class II
and CD1 group 1 presentation molecules and presentable (peptide
and non-peptide) ligands [39]. Human CD8
+ T-cells from PPD-
responsive adults and BCG-vaccinated infants recognized newly
identified Mtb peptides with predicted HLA-E binding motifs,
resulting in T cell proliferation. The responding cells had cytotoxic
activity, and lysed target cells in a peptide-specific and HLA-E
dependent fashion, strongly suggesting peptide/HLA-E cognate
recognition via the TCR. Moreover, these epitopes likely are also
recognized during infection since live mycobacterium infected
monocytes were lysed by HLA-E/peptide stimulated effector T
cells. In addition to their cytolytic capacity, HLA-E/peptide
reactive T-cell lines also had strong immunoregulatory properties,
since they inhibited proliferation of unrelated responder T-cells.
This suppression was dose-dependent, required cell-cell contact
and was mediated, at least in part, by membrane bound TGFb1
(mTGFb1). Thus, the human CD8
+ T-cell lines described here
have dual functionality, in that they are able to lyse antigen loaded
target cells, which may be linked to protective effector mechanisms
in controlling intracellular infection, and to exert immunoregula-
tory activities. T cell lines or ‘clones’ derived from limiting dilution
assays demonstrated that cytotoxic and regulatory activity can be,
but are not necessarily mediated by the same HLA-E/peptide
induced cells.
It has previously been described that antigens from Salmonella
typhi [9] and cytomegalovirus [7] can be presented by human
HLA-E molecules. In the case of Mtb, 2 HLA-E restricted T-cell
clones have been reported, yet the precise peptides from Mtb that
were recognized (which were present in Mtb-DC-conditioned
medium) remain unknown. It is also unknown to what extent these
T-cell clones might represent the global response against Mtb in
humans [13]. In general, the number of potential HLA-E peptide
epitopes identified in the literature and the nature of T-cells
recognizing them has been very limited. Interestingly, HLA-E is
enriched in the Mtb phagosome compared to regular HLA class I
molecules (HLA-A2), suggesting that HLA-E may have unique
functions in presenting phagosomal antigens, which is particularly
relevant to Mtb since it resides in immature phagosomes [40].
To the best of our knowledge, the current study describes the
first large scale analysis of pathogen derived, putative HLA-E
binding peptides, revealing a significant contribution of HLA-E
dependent peptide presentation in pathogen recognition. More-
over, our study represents the first genome wide pathogen
Figure 6. Suppression is mediated by membrane-bound TGFb.
(A) Co-culture assay of Treg line (donor 4, peptide 55) with responder T-
cell clone (Rp15 1-1) in the presence of 0.5 mg/ml cognate peptide and
HLA-DR3
+ APCs results in inhibition of proliferation ([
3H] TdR uptake;
left graph). Right graph: Addition of LAP in this setting in the presence
of a fixed number (2.5610e4) of Tregs resulted in a dose-dependent
abrogation of suppression. Experiment representative of 4 lines in 3
different experiments. *: p,0.05, **:p,0.01, ***: p,0.001 (Students T-
test). (B) Surface staining of membrane bound TGFb. T-cell lines were
stained for the presence of membrane bound TGFb using the TB21
monoclonal antibody, gated on CD25
+ cells. mTGFb staining was
observed on all 4 lines, although to a variable extent, the isotype
control was used to place markers and was negative for all lines
(bottom).
doi:10.1371/journal.ppat.1000782.g006
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with a potential HLA-E binding motif. In our experiments,
epitope prediction scores, peptide binding affinity measurements,
T-cell recognition and functional profiling were used to guide
peptide selection. Interestingly, some of the peptides studied were
not capable of competing with the high affinity natural ligand in
the peptide/HLA-E competition assay, regardless of being
efficiently recognized by T-cells. Thus, for prediction of HLA-E
binding peptides, some caution seems warranted when selection is
based solely on HLA-E binding affinity in biochemical, cell free
binding assays. In addition, the results show, in line with literature
on peptides bound by HLA-class Ia and II molecules, that high
affinity peptide binding does not necessarily translate into high
efficiency T-cell recognition. This may be due to the lack of
processing, induction of tolerance or alternative binding registers
not involved in TCR engagement. Although the subsequent
rounds of peptide prediction (initially motif scores were used,
followed by discriminant analysis and finally diversity ranking) and
binding aimed to improve the prediction algorithms, this might
not have been unequivocally successful: although numbers are
sometimes small, the data suggest that peptides derived from all 3
prediction rounds bind equally well and are recognized by T-cells
to a similar extent. Thus the motif was not further improved and
dedicated studies should be performed for motif optimization.
The abundant recognition of Mtb peptides with an HLA-E
binding motif, points towards a contribution of non-classical HLA
molecules to pathogen specific immunity in general and perhaps
more particular for mycobacteria in view of Mtb’s phagosomal
localization [40]. We hypothesize that functional effector T-cells
induced by HLA-E binding Mtb peptides contribute to pathogen
clearance in vivo. Peptides containing a HLA-E binding motif were
also recognized by infants following BCG vaccination, suggesting
that antigen presentation of mycobacterial peptides in vivo can
result in activation of CD8
+ T-cell immunity in the context of
HLA class Ib molecules. This is further supported by the observed
lysis of M. bovis BCG infected monocytes by the HLA-E/peptide
stimulated T-cell lines, suggesting specific recognition of myco-
bacterium infected target cells by HLA-E restricted T- cells.
Since HLA-E is a highly conserved molecule, one might have
expected more uniform recognition patterns of synthetic peptides
derived from Mtb between different individuals. However, as
shown in the present study, peptide recognition is rather diverse
and none of the peptides is recognized by all responsive or
vaccinated donors. Thus, the repertoire of HLA-E binding
peptides from Mtb -and perhaps also other antigens- may be
larger than initially anticipated. Nevertheless, a small number of
peptides (e.g. #62) was recognized by over 30% of the PPD
responsive donors in 2 quite different cohorts. It remains also
possible that a proportion of the response could have been due to
proliferation in response to classical HLA class Ia family members
that can bind the same peptides. However, in the donors tested the
motifs of the recognized peptides did not conform to any of the
classical HLA-A and B allele specific peptide binding motifs.
Some peptides were also recognized by donors who did not
have detectable T-cell responses to PPD in vitro. We do not have
detailed information about these (anonymous bloodbank) donors
and can therefore not exclude that some donors may have
encountered mycobacteria in the past [41]. The fact that certain
peptides in these donors were more able to induce CD8
+ T cell
responses compared to PPD might be due to their preprocessed
nature, facilitating high efficiency antigen presentation and/or to
their higher molarity, since proteins and peptides all were tested at
10 mg/ml concentrations, regardless of their molecular mass.
Umbilical cord blood samples, however, displayed lower levels of
proliferation, suggesting that sensitization to (environmental)
(myco)bacteria had caused proliferation in non-responders. Of
note, some of the peptides recognized by PPD non-responder
donors are not unique to Mtb, but are also present in
environmental mycobacteria and other bacteria, such that the
observed responses may have been the result of cross-induced
immunity. The impact of environmental (myco)bacteria on
induction of T-cell immunity needs further study [41].
CD8
+ T-cells that recognize HLA-E restricted S. typhi derived
peptides can produce IFNc and lyse infected target cells,
indicating a role in host defense [9]. Such a functional
contribution of HLA class Ib genes to host defense is interesting,
particularly in view of the low genetic polymorphism of HLA class
Ib genes. Murine studies have shown that the HLA-E homologue
Qa-1 can not only be recognized by CTLs but also induce Tregs
[42]. Qa-1 knockout mice had increased CD4
+ T-cell responses
upon infection and vaccination, due to the lack of Qa-1 restricted
CD8
+ Tregs [42]. Indeed, our CD8
+ T-cell lines were also able to
inhibit T-cell proliferation via membrane bound TGFb. In theory,
both functions may be the property of a single cell population or
alternatively be expressed by 2 subpopulations. Our preliminary
experiments show that single-cell derived ‘T-cell clones’ can
possess either both regulatory and cytotoxic dual activity or single
functionality. This demonstrates that cytotoxic and regulatory
activity are not necessarily mediated by, yet can be exerted by the
same cellular populations.
The role of Tregs in TB infection is debated although some
recent studies in murine infection models show that they preclude
efficient pathogen clearance and are therefore harmful to the host
[43,44]. Although direct evidence is lacking, indirect evidence
indicates that Tregs are involved in active disease in humans as
well. First, CD4
+ and CD8
+ Tregs were increased at the site of
infection, both in mycobacterium induced granulomas [32,45] and
at sites of extrapulmonary TB compared to the circulation [45–
48]. Secondly, the frequency and number of Tregs was increased
in the circulation of patients with active TB compared to controls,
and normalized after treatment [44–47]. Depletion of Tregs in vitro
increased IFNc production in response to mycobacterial antigens
[47,48]. Thus the presence and activity of Tregs is associated with
(and a biomarker of) active TB disease. In vitro stimulation with
peptides containing a HLA-E binding motif resulted in the
induction of functionally active regulatory T-cells. If similar
activity occurs following vaccination with putative HLA-E binding
Mtb peptides, these Tregs may regulate rather than mediate
pathogen eradication. In this context, it is interesting to note,
however, that it was recently described that Treg activity can also
contribute to host immune protection against infectious agents, by
allowing a timely entry of effector cells during viral infections [49].
The relative contribution of these different functional T-cell
properties remains to be clarified in future studies.
Another open question is whether peptide recognition in the
context of HLA-E is an exclusive gateway for CD8
+ Treg
induction. To decipher if HLA-E preferentially activates T-cells
with regulatory properties compared to classically restricted T-
cells, more detailed quantitative comparisons will be needed
between classically and non-classically restricted T-cells regarding
the frequency of Tregs within these populations. Until these
analyses have been completed we can only conclude that HLA-E
restricted cells can have regulatory properties. Previously we have
described CD8
+ Tregs upon in vitro stimulation with live BCG
[32], but we have not confirmed or excluded a role for HLA-E in
antigen presentation to these CD8
+ Tregs. However these cells
had a different phenotype and used a different mechanism of
suppression (i.e. via CCL4), thus suggesting that the CD8
+ T(reg)-
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multiple subsets with regulatory activity.
At this stage, we can only speculate why T-cells that recognize
foreign, pathogen-derived peptides in the context of HLA-E might
have dual (cytolytic and regulatory) functions. The low level of
variation in HLA-E proteins suggests a similarity with pattern
recognition in innate immunity, possibly with a primary default
effector T-cell response as a consequence. Natural ligands of HLA-
E are signal sequences derived from other HLA class I molecules;
in all cases the immune system aims to avoid harmful immunity to
these self-antigens. HLA-E is amongst the few HLA molecules
expressed in the human throphoblast, which invades the maternal
part (the decidua) of the placenta [50]. Expression of HLA class I
alleles is necessary to evade immune surveillance by NK cells, but
recognition of allo-antigens by the maternal immune system is
undesirable for the fetus. Increased Treg numbers are observed in
the placenta, mostly at the site of feto-maternal contact [51,52],
perhaps as a result of HLA-E presented peptides. Pathogen
derived peptides might have hijacked this mechanism in order to
be able to induce pathogen specific Tregs that can down regulate
host immunity. This balance between effector and regulatory
immunity in the context of HLA-E might allow partial clearance
of pathogen from the host, thus providing sufficient levels of
protection while avoiding excessive inflammation and pathology,
but at the expense of pathogen persistence and chronic infection.
Future studies need to dissect this ‘‘primordial’’ host immune
response pathway, and to determine the relative importance of
effector vs. immunoregulatory activities within the HLA-E based
antigen presentation system in infection and other human diseases.
Materials and Methods
Ethics statement
Human participation in this research was according to the U.S.
Department of Health and Human Services and good clinical
practice guidelines. This included protocol approval by the Leiden
University Medical Center Ethics Committee and the University
of Cape Town research Ethics Committee and written (parental)
informed consent by all donors. Anonymous buffy coats from
healthy blood bank donors were only used if donors had consented
scientific use of blood products.
Prediction of HLA-E binding Mtb peptides
A set of open reading frames corresponding to all (predicted)
proteins from the Mtb (H37Rv) genome was scanned using a semi-
quantitative scoring matrix to search for nonameric peptides with
the potential to bind HLA-E. The matrix was adapted by a motif
change and inclusion of a quantitative matrix, derived from the
results of Miller et al [20]. The top scoring set of peptides was
combined with a set of legacy peptides of known provenance and a
set of other available peptides as potential negative controls
(peptides 1–43). The resulting set of peptides was synthesized and
tested in in vitro binding assays. This data was used to create a
quantitative discriminant model [25]; ranking peptides in terms of
their likelihood of binding HLA-E, yielding a second set of
peptides (peptides 44–50). The ranked set of Mtb peptides was
then subjected to diversity analysis using Z score descriptors for
each position [26,53,54] to generate a third set of peptides which
were synthesized and tested for HLA-E binding and immunoge-
nicity (peptides 51–69).
Peptide synthesis
Peptides were made on a Syro II peptide synthesizer (Multi-
Syntech, Witten, Germany) using TentagelS AC resins (Rapp,
Tu ¨bingen, Germany) in combination with Fmoc chemistry
[55,56]. The purity of the peptides was checked on reverse phase
C18 HPLC (Vydac 218TP5415, Grace, Deerfield, IL, USA). As
the standard peptide VMAPC(Fl)TLLL was used. This peptide
is derived from the human HLA-B*0801 leader peptide
VMAPRTLLL. Fluorescence labeling of the cysteine in the
precursor peptide was performed with 4-(iodoacetamido)fluores-
cein (Fluka Chemie AG, Buchs, Switzerland) in a mixture of
250 ml Na-phosphate buffer 0.15 M, pH 8.0 and 150 ml acetoni-
trile [55].
HLA-E-peptide binding assay
Recombinant HLA-E*0103 (kind gift of Dr. V.M. Braud,
Universite ´ de Nice-Sophia, Valbonne, France) was overexpressed
in E. coli and purified as described previously for HLA-A*0201
[57], and then dissolved in 8M urea and stored in stock solutions
(50 mM) at 220uC until use. The integrity of the protein was
confirmed by TOF-MALDI mass spectrometry. Human b2-
microglobulin was purchased from Sigma (St. Louis, MO) and
dissolved in H2O.
HLA-E*0103 was titrated in the presence of 100 fmol
fluorescent standard peptide to determine the recombinant HLA
concentration necessary to bind 20–50% of the total fluorescent
signal. All subsequent inhibition assays were then performed at this
concentration. HLA-E*0103 was incubated in 96-well plates
(polypropylene, serocluster, Costar) at RT (pH7) for 24 h with
15 pmol b2M and 100 fmol fluorescent labeled standard peptide
in assay buffer (100 mM Na-phosphate, 75 mM NaCl, 1 mM
CHAPS), protease inhibitor mixture (1 mM chymostatin, 5 mM
leupeptin, 10 mM pepstatin A, 1 mM EDTA, 200 mM pefabloc)
and 2 ml of the peptides of which HLA-E binding capacity was to
be determined. As a standard peptide VMAPC(FL)TLLL was
used. The HLA-peptide complexes were separated from free
peptide by gel filtration on a Synchropak GPC 100 column
(250mm 64.6mm; Synchrom, Inc., Lafayette, Indiana). Fluores-
cent emission was measured at 528 nm on a Jasco FP-920
fluorescence detector (B&L Systems, Maarssen, The Netherlands).
As HPLC running buffer, assay buffer containing 5% CH3CN was
used. The percentage of peptide bound was calculated as the
amount of fluorescence bound to MHC divided by total
fluorescence. The concentration of peptide yielding 50% inhibi-
tion was deduced from the dose-response curve. Each peptide was
tested in at least two separate experiments.
Donors
Anonymous buffy coats were collected from healthy blood bank
donors (Dutch, adults) that all had signed informed consent. No
clinical information is available for the donors other than that they
were healthy, and had no chronic viral infections or other
contraindications for donating blood. BCG in The Netherlands is
only administered to people at risk for TB exposure and the TB
incidence in the Netherlands is extremely low, such that the vast
majority of our donors (.95%) is highly unlikely to have been
vaccinated with BCG, or to have had exposure to Mtb. PBMCs
were isolated by density centrifugation and directly tested in a
lymphocyte stimulation test to analyze their reactivity to Mtb
derived antigens. PBMCs (5610e5/well) were stimulated with
PHA (2 mg/ml, Remel, Oxoid, Haarlem, The Netherlands) and
PPD (5 mg/ml, Statens Serum Institute, Copenhagen, Denmark)
in Iscove’s modified Dulbecco’s medium (IMDM, Invitrogen,
Breda, The Netherlands) containing 10% pooled human serum.
After 6 days supernatants were tested in an IFNc ELISA (U-
CyTech, Utrecht, The Netherlands). IFNc production $100 pg/
ml was considered a positive response [58].
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stimulation as well as 10 donors that did not respond were selected
for the immunogenicity screening of peptides with predicted HLA-
E binding motifs. The average IFNc production in response
to PPD was 2067 pg/ml, median 1213 pg/ml (range 275–
10,000 pg/ml).
Anonymous umbilical cord blood (UCBs) cells were provided by
Dr. S. Scherjon (dept. of Obstetrics, Leiden University Medical
Center), all were derived from full term-pregnancies and delivery
by caesarian section.
As a second group we analysed BCG vaccinated infants, to
examine whether BCG vaccination could elicit response against
predicted HLA-E binding epitopes. Similar proliferation experi-
ments were performed using cells from 10 week old infants (n=12,
from South Africa, with informed consent from their parents) that
had received BCG vaccination at birth. Peptides were selected
after the screening in healthy Dutch adults was completed and
included the 4 peptides selected for detailed analysis, the top 3
peptides recognized by Dutch donors and 3 high affinity HLA-E
binding peptides, irrespective of recognition by Dutch donors.
Analysis of T-cell proliferation induced by predicted
HLA-E binding Mtb peptides
PBMCs were CFSE labeled (5 mM, Invitrogen), 1610e5 cells
were stimulated with predicted HLA-E binding peptides at a
concentration of 10 mg/ml in IMDM with 10% human serum in
the presence of 5 ng/ml IL-7 (Peprotech, Rocky Hill, NJ). Positive
and negative controls were included in each assay and included
PHA (2 mg/ml), PPD (5 mg/ml), ESAT-6 and CFP-10 (10 mg/ml
each) or culture medium only. On day 7 of culture, IL-2 was
added to a final concentration of 10 U/ml (Cetus, Emeryville,
CA). On day 10, supernatants were collected and stored at
220uC. Cells were harvested, replicates (n=6) pooled and stained
using CD3-PerCP, CD8-APC and CD56-PE (all BD Biosciences,
Alphen aan de Rijn, The Netherlands) before acquisition on a
FACS Calibur flowcytometer using CellQuest Pro software (BD
Biosciences) or on a LSRII flowcytometer using FACS Diva
software (BD Biosciences).
To analyze proliferation, cells were gated on lymphocytes,
followed by gating on CD3
+CD8
+CD56
2 cells. The percentage of
proliferation was calculated using geometric means by subtracting
the geometric mean of all cells from the geometric mean of the
undivided population. Subsequently the percentage was calculated
by: (delta geo mean of sample- delta geo mean of negative
control)/ delta geo mean of maximal proliferation.
To demonstrate that putative HLA-E binding Mtb peptide
directed CD8
+ T-cell proliferation in PBMC cultures can indeed
be induced by HLA-E peptide presentation we performed the
following experiment. CD8
+ cells were purified from PBMCs from
3 donors (2,4 and 6) by positive selection using magnetic beads
(MACS, Milteny Biotec, Auburn, CA) and labeled with CFSE
(5 mM, Invitrogen), the CD8
2 fraction was irradiated at 30 Gy
and added to the culture as feeders. Peptides (25 mg/ml) were
loaded onto K562 cells with or without HLA-E*0103 (kind gift of
Dr. E. Weiss, Ludwig-Maximilians-Universita ¨t, Munich, Ger-
many) [59] during an overnight period at 26uC, followed by
stabilization at 37uC for at least 2 hours. After washing to remove
any free peptide, peptide loaded target cells were irradiated at
50 Gy and HLA-E expression was checked by FACS. CFSE
labeled CD8
+ cells (1610
4) were co-cultured with peptide loaded
K562 cells (5610
3) with or without HLA-E in the presence of
irradiated self CD8
2 cells (2,5610
4) in 96 well roundbottom plates
(12 wells per condition). Cells were cultured in IMDM+10%
human serum supplemented with 5 ng/ml IL-7 and with
costimulatory antibodies (CD28 (1 mg/ml, CLB, Amsterdam,
The Netherlands) & CD49d (1 mg/ml, BD Biosciences)). On day
7 of co-culture, IL-2 was added to a final concentration of 10 U/
ml (Cetus, Emeryville, CA). On day 10, cells were harvested and
stained using CD3-Pe-Cy7, CD8-APC and CD56-Alexa 700 (all
BD Biosciences, Alphen aan de Rijn, The Netherlands) before
acquisition on a LSRII flowcytometer using FACS Diva software
(BD Biosciences). For analysis, cells were gated on CD8
+CD56
2
and CFSE proliferation was analysed.
Generation of T-cell lines & clones
PBMCs were stimulated with single predicted HLA-E binding
peptides (10 mg/ml) in IMDM with 10% pooled human serum
and 5 ng/ml recombinant human IL-7. On day 6 of culture IL-2
was added to a final concentration of 25 U/ml.
CD8
+ T-cells were isolated from peptide induced T-cell lines at
day 13 by magnetic bead separation (MACS, Milteny Biotec,
Auburn, CA). For restimulation, feeder cells were pre-pulsed with
10 mg/ml of the specific peptide for 4 hours, washed and
irradiated (30 Gy), 1610e5 prepulsed feeder cells were added to
2610e4 T-cells in the presence of 125 U/ml IL-2 (Cetus) in
IMDM (Invitrogen) with 10% pooled human serum.
T-cell clones were generated by limiting dilution of T-cell lines
of donor 2 which were directed against peptide 62. Cells were
stimulated with peptide pre-pulsed (10 mg/ml for 3 hours),
irradiated (30Gy) allogeneic feeders in the presence of IL-2
(125 U/ml; Cetus). Cell growth in the 0.1 cell/well conditions was
considered clonal, although formal clonality assessment was not
performed. Cells were maintained in IL-2 and tested for
suppression and cytolytic activity at the end of the stimulation
cycle.
Flow cytometry
T-cell lines were analyzed in detail by flowcytometry both
directly from culture as well as after overnight restimulation with
aCD3/28 beads (Dynal T-cell expander beads, Invitrogen).
Antibodies used for staining included CD3-Pacific blue/ PE-
Cy7, CD8-Am Cyan, CD25-APC-Cy7, CD56-PE-Cy5, CD94-
PE, CD16-Pacific blue, TCRab-FITC, IFNc-Alexa 700 (all BD
Biosciences). Moreover, we used NKG2A-PE from Immunotech
(Mijdrecht, The Netherlands), NKG2C-PE and NKG2D-PE
(R&D systems, Abingdon, UK). In addition cells were stained
for LAG-3 (17B4 kind gift of Dr. F. Triebel, Immutep S.A.,
Chatenay-Malabry, France) in combination with goat-anti-mouse-
PE (Dako Cytomation, Heverlee, Belgium); CCL4-FITC (R&D
systems), FoxP3-Pe-Cy5 (Ebioscience, San Diego, CA), Granzyme
B-APC (CLB, Amsterdam, The Netherlands), rabbit anti-human
granulysin (kind gift of Dr. A. Krensky, Stanford, CA) in
combination with goat-anti-rabbit FITC (BD Biosciences). Mem-
brane bound TGF-b1 was detected using the PE conjugated
monoclonal TB21 (IQproducts, Groningen, The Netherlands).
Intracellular staining was done after overnight incubation with
Brefeldin A (3 mg/ml, Sigma) using Intrastain reagents (Dako
Cytomation). Samples were acquired on a LSRII flowcytometer
and analyzed using FACSDiva software (BD Biosciences). Scoring
in Figure 3B was based on the percentage of cells that expressed
the particular marker, markers expressed by 10% of the cells, or
more, were considered positive.
Cytotoxicity assays
Single HLA-E expressing cells lines (K562 cells) were used to
test the capacity of the T-cell lines to lyse target cells that present
the peptide in HLA-E (kind gift of Dr. E. Weiss, Ludwig-
Maximilians-Universita ¨t, Munich, Germany) [59]. Lines were
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K562 cells, a leukemic line that does not express any HLA-class I
molecules as previously described [59]. In order to obtain stable
surface expression of HLA-E one of its natural ligands needs to be
co-expressed; in this case this was achieved by cotransduction of
the signal peptide of HLA-B7. HLA-E expression in HLA-E
transfectants was inducible by culturing the cells at 26uC for at
least one day. Subsequently predicted HLA-E binding Mtb
peptides (10 mg/ml) were added for 16 hours at 26uC and HLA-
E-peptide dependent expression was stabilized by a final
incubation at 37uC for 2 hours. Transfectants were cultured in
Iscove’s modified Dulbecco’s medium (Invitrogen, Breda, The
Netherlands) supplemented with 10% FCS (Greiner Bio-One
B.V., Alphen aan de Rijn, The Netherlands) and 200 mg/ml G418
(Invitrogen). Transfectants were always checked for HLA-E
expression prior to experiments using FACS staining for HLA-
class I (W6/32) and more specifically for HLA-E (3D12, kind gift
of Dr. D. Geraghty, Fred Hutchinson Cancer Research Center,
Seattle, WA).
Peptide loaded HLA-E transfectants were labeled with 1 mCi
51Cr before co-culture with different ratios of T-cell lines. After 4
to 5 hours of co-culture
51Cr release was measured and specific
lysis calculated using the following formula: (sample lysis –
medium)/(maximum lysis – medium) [60].
To demonstrate processing and recognition of naturally
presented epitopes. T-cell lines were tested for recognition of
BCG infected monocytes. Allogeneic PBMCs, completely mis-
matched for HLA-A, B & C (including supertypes) for all T-cell
donors, and derived from 2 different PBMC donors, were plated
for 7 days (150.000 cells/ well in 96 well plates) to obtain adherent
monocytes. After washing cells were infected with live BCG (MOI
5, Montreal strain [32]) and labeled with 1 mCi
51Cr over night.
After washing, cells were co-cultured for 5 hours with T-cell lines
and assessment of
51Cr release. A control cytotoxic CD8
+ T cell
clone, reactive with the male HY antigen presented by HLA-A2
was included to control for aspecific lysis of infected monocytes
(kindly provided by the laboratory of Prof E. Goulmy, department
of Immunohematology and Blood Transfusion, LUMC, Leiden,
previously described in [61]). HLA-A2 positive B-cells expressing
the male HY antigen were used as natural targets for this CTL
clone.
Suppression assays
T-cell lines specific for predicted HLA-E binding peptides were
tested for their capacity to inhibit proliferation of a well
characterized Th1 responder clone (Rp15 1-1) [33]. T-cell lines
were added in various doses to co-cultures containing 1610
4 Th1
cells, 5610
4 HLA-DR3 matched, irradiated PBMCs as APCs
(20 Gy) and 0.5 mg/ml specific Mtb hsp65 p3–13 peptide. After 3
days, proliferation was measured by [
3H] TdR incorporation.
To test if the reduced thymidine uptake by the responder T-cell
clone (Rp15 1-1) was not the consequence of cell lysis we
performed a CFSE labeling experiment, which included a control
CD4
+ T-cell clone (R2F10, HLA-DR2 restricted, specific for M.
leprae hsp65 p418–427) as indicator for the input signal. Rp15 1-1
cells were labeled with a low dose CFSE (0.005 mM), whereas
R2F10 was labeled with a high dose of CFSE (5 mM). Both CFSE
labeled responder and control clones were co-cultured with the
Mtb hsp65 p3–13 peptide, HLA-DR3 matched APCs and
different concentrations of Tregs. After 16 hours (before divisions
of the responder clone occur) cells were harvested, stained for
CD3, CD4 and CD8 and analyzed by flowcytometry on a BD
LSRII. The number of cells of both responder and control T-cell
clones were compared: a ratio close to 1 indicates that the
responder clone is not lysed by the Tregs, a ratio below 1 indicates
lysis of the responder clone. Lysis of both responder and control T-
cell clone can be excluded by comparison of conditions with and
without Tregs.
To decipher the mechanism of suppression mediated by the
HLA-E restricted Tregs, we performed inhibition experiments
with the Latency Associated Peptide (LAP) [38]. LAP binds to
TGFb1 and thereby limits its activity. In these experiments, Tregs
were titrated onto the Rp15 1-1 responder T-cell clone, in the
presence of peptide (0.5 mg/ml), APCs and different concentra-
tions of LAP (R&D systems); [
3H] TdR incorporation was assessed
after 3 days of co-culture.
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